Eagle Pharmaceuticals Inc. announced that it has completed the submission of its 505(b)(2) New Drug Application for Ryanodex for the treatment of exertional heat stroke (EHS) to the U.S. Food and Drug Administration.

Vifor Fresenius Medical Care Renal Pharma obtains rights to commercialize RAYALDEE in Europe, Canada and certain other international markets; OPKO Health to receive up to $282 million in upfront and milestone payments, plus tiered double-digit royalties.